Advanced search
Publication Cover
Journal of Market Access & Health Policy Volume 5, 2017 - Issue 1
Journal homepage
3,903
Views
16
CrossRef citations to date
0
Altmetric
ARTICLE

Analysis of health economics assessment reports for pharmaceuticals in France – understanding the underlying philosophy of CEESP assessment

Mondher ToumiFaculté de Médecine, Laboratoire de Santé Publique, Aix-Marseille Université, Université de la Méditerranée, Marseille Cedex, FranceCorrespondence[email protected]
View further author information
,
Anastasiia MotrunichHealth Economics and Outcomes Research Department, Creativ-Ceutical, Paris, FranceView further author information
,
Aurélie MillierHealth Economics and Outcomes Research Department, Creativ-Ceutical, Paris, FranceView further author information
,
Cécile RémuzatHealth Economics and Outcomes Research Department, Creativ-Ceutical, Paris, FranceView further author information
,
Christos ChouaidFaculté de médecine, INSERM U955 and Université Paris Est (UPEC)UMR U955, Créteil, France;Département de Pneumologie et Pathologie Professionnelle, Centre Hospitalier Intercommunal DHU-ATVB, Créteil, FranceView further author information
,
Bruno FalissardINSERM Unit U669 (Public Health and Mental Health), University Paris-Sud, Paris, FranceView further author information
&
Samuel AballéaFaculté de Médecine, Laboratoire de Santé Publique, Aix-Marseille Université, Université de la Méditerranée, Marseille Cedex, France;Health Economics and Outcomes Research Department, Creativ-Ceutical, Paris, FranceView further author information
 show all
Article: 1344088 | Received 16 May 2017, Accepted 13 Jun 2017, Published online: 16 Jul 2017

Citations (16)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (3)

Xavier Armoiry, Hans-Martin Späth, Anna-Maria Henaine, Claude Dussart, Carl Counsell & Martin Connock. (2021) Ocrelizumab not recommended in France for patients with primary progressive multiple sclerosis while recommended in England: a review comparing the assessment by HAS and NICE. Expert Opinion on Biological Therapy 21:6, pages 741-747.
Read now
Evelien Moorkens, Hannah Broux, Isabelle Huys, Arnold G. Vulto & Steven Simoens. (2020) Economic evaluation of biosimilars for reimbursement purposes – what, when, how?. Journal of Market Access & Health Policy 8:1.
Read now
Xavier Armoiry, Hans-Martin Spath, Aileen Clarke, Martin Connock, Paul Sutcliffe & Claude Dussart. (2019) Comparison of health technology assessment for new medicines in France and England: an example based on ixazomib for patients with relapsed or refractory multiple myeloma. Journal of Market Access & Health Policy 7:1.
Read now

Articles from other publishers (13)

Giorgio Casilli, Dario Lidonnici, Claudio Jommi, Marika De Nigris & Armando A. Genazzani. (2023) Do France, Germany, and Italy agree on the added therapeutic value of medicines?. International Journal of Technology Assessment in Health Care 39:1.
Crossref
Wolfgang Greiner & Julian Witte. (2022) Grundkonzepte und Einsatz von Kosten-Nutzen-Bewertungen im internationalen Überblick. Zeitschrift für Evidenz, Fortbildung und Qualität im Gesundheitswesen 174, pages 111-118.
Crossref
Valentine Grumberg, Stéphane Roze, Julie Chevalier, John Borrill, Anne-Françoise Gaudin & Sébastien Branchoux. (2022) A Review of Overall Survival Extrapolations of Immune-Checkpoint Inhibitors Used in Health Technology Assessments by the French Health Authorities. International Journal of Technology Assessment in Health Care 38:1.
Crossref
Ramon Schaefer, Diego Hernandez, Lorenz Selberg & Michael Schlander. (2021) Health technology assessment (HTA) in England, France and Germany: what do matched drug pairs tell us about recommendations by national HTA agencies?. Journal of Comparative Effectiveness Research 10:16, pages 1187-1195.
Crossref
Julian Witte & Wolfgang Greiner. 2021. Arzneimittel-Kompass 2021. Arzneimittel-Kompass 2021 3 17 .
Angelica Carletto, Matteo Zanuzzi, Annalisa Sammarco & Pierluigi Russo. (2020) Quality of health economic evaluations submitted to the Italian Medicines Agency: current state and future actions. International Journal of Technology Assessment in Health Care 36:6, pages 560-568.
Crossref
Bruno Bregman, Siguroli Teitsson, Isabella Orsini, François-Emery Cotté, Adenike Amadi, Andriy Moshyk, Stéphane Roze & Anne-Françoise Gaudin. (2020) Cost–Utility Analysis of Nivolumab in Adjuvant Treatment of Melanoma in France. Dermatology and Therapy 10:6, pages 1331-1343.
Crossref
V. V. Omelyanovskiy, A. V. Nikitina, V. A. Lemeshko & G. R. Khachatryan. (2020) Drug provision and health technology assessment in France. FARMAKOEKONOMIKA. Modern Pharmacoeconomic and Pharmacoepidemiology 13:1, pages 71-83.
Crossref
Mackenzie Mills & Panos Kanavos. (2020) Do pharmaceutical budgets deliver financial sustainability in healthcare? Evidence from Europe. Health Policy 124:3, pages 239-251.
Crossref
David Epstein & Jaime Espín. (2020) Evaluation of new medicines in Spain and comparison with other European countries. Gaceta Sanitaria 34:2, pages 133-140.
Crossref
Claudio Jommi, Patrizio Armeni, Francesco Costa, Arianna Bertolani & Monica Otto. (2020) Implementation of Value-based Pricing for Medicines. Clinical Therapeutics 42:1, pages 15-24.
Crossref
Pierre Ducournau, Cornelia Irl, Iain Tatt, Mary McCarvil & Marlene Gyldmark. (2019) Timely, consistent, transparent assessment of market access evidence: implementing tools based on the HTA Core Model® in a pharmaceutical company. International Journal of Technology Assessment in Health Care 35:1, pages 10-16.
Crossref
Szymon Jarosławski, Eve Hanna, Monique Dabbous, Lylia Chachoua & Mondher Toumi. 2019. Regulatory and Economic Aspects in Oncology. Regulatory and Economic Aspects in Oncology 39 55 .

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.